Food and Drug Administration Commissioner Scott Gottlieb, M.D., yesterday announced the agency’s 2019 agenda to address the opioid epidemic. Among other actions, the agency is considering using its authority under the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 to mandate short-duration packaging for outpatient dispensing of certain solid, oral dosage forms of immediate-release opioid analgesics to treat acute pain, and require manufacturers to develop technologies such as mail-back pouches to dispose of unused opioid medications. FDA also plans to announce changes to strengthen the Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl medicines, and issue updated guidance to promote the development of non-opioid drugs to treat pain.

Related News Articles

Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM)…
Headline
Mallinckrodt Pharmaceuticals today announced an agreement in principle on a settlement to resolve all opioid-related claims against the company in…
Headline
Public and private entities can apply for $1 million grants for a three-year period to enhance or expand opioid and other substance use disorder services in…
Headline
Rep. Vicky Hartzler, R-Mo., House Energy and Commerce Committee Ranking Member Greg Walden, R-Ore., and other Republicans on the committee last week asked the…
Headline
The House Energy and Commerce Subcommittee on Oversight and Investigations today held a hearing to highlight how federal funds have helped states combat…